darunavir has been researched along with Viremia in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 11 (91.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bayés-Genís, A; Blanco, J; Bonjoch, A; Clotet, B; Echeverría, P; Gómez-Mora, E; Negredo, E; Pérez-Alvarez, N; Puig, J; Roura, S | 1 |
| Blanco, J; Clotet, B; Gómez-Mora, E; Hernández-Rodríguez, A; Marfil, S; Martínez-Bonet, M; Martinez-Picado, J; Matas, L; Moltó, J; Morón-López, S; Muñoz-Fernández, MA; Puertas, MC; Santos, JR; Urrea, V | 1 |
| Benmarzouk-Hidalgo, OJ; Gutiérrez-Valencia, A; Lopez-Cortes, LF; Martín-Peña, R; Pérez-Romero, P; Ruiz-Valderas, R; Torres-Cornejo, A; Viciana, P | 1 |
| Arribas, JR; Bernardino, JI; Estébanez, M; González-García, JJ; Mingorance, J; Montes, ML; Pérez-Valero, I; Stella-Ascariz, N; Zamora, FX | 1 |
| Hazuda, DJ; Johnson, AM; Lifson, JD; Ling, B; Piatak, M; Rogers, L; Russell-Lodrigue, K; Veazey, RS | 1 |
| Imai, Y; Kawamoto, M; Kohara, N; Sekiya, H; Togo, M; Yoshimura, H | 1 |
| Back, D; Clotet, B; Curran, A; Di Yacovo, MS; Else, L; Ferrer, E; Gisslén, M; Moltó, J; Niubò, J; Podzamczer, D; Tiraboschi, JM; Vila, A; Zetterberg, H | 1 |
| BenMarzouk-Hidalgo, OJ; Gutiérrez-Valencia, A; López-Cortés, LF; Ruiz-Valderas, R; Torres-Cornejo, A; Viciana, P | 1 |
| Andreoni, M; Antinori, A; Castagna, A; Ceccherini-Silberstein, F; Celesia, BM; Cozzi-Lepri, A; d'Arminio Monforte, A; De Luca, A; Galli, M; Gianotti, N; Mussini, C; Pinnetti, C; Spagnuolo, V | 1 |
| Arazo Garcés, P; Omiste Sanvicente, T | 1 |
| Acosta, EP; Barreca, ML; Chirullo, B; Collins, M; Della Corte, A; Greenhouse, J; Iraci, N; Lewis, MG; Norelli, S; Savarino, A; Shytaj, IL; Yalley-Ogunro, J | 1 |
| Bocket, L; Calvez, V; Dos Santos, G; Flandre, P; Fourati, S; Katlama, C; Lambert-Niclot, S; Marcelin, AG; Masquelier, B; Pakianather, S; Sayon, S; Soulie, C; Valantin, MA; Wirden, M | 1 |
1 review(s) available for darunavir and Viremia
| Article | Year |
|---|---|
[Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].
Topics: Adult; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Darunavir; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Multicenter Studies as Topic; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Viremia | 2008 |
4 trial(s) available for darunavir and Viremia
| Article | Year |
|---|---|
Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs.
Topics: Adult; Antiretroviral Therapy, Highly Active; Darunavir; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Immunity, Cellular; Inflammation; Lopinavir; Lymphocyte Activation; Male; Middle Aged; Pilot Projects; Proof of Concept Study; Raltegravir Potassium; RNA, Viral; Viremia; Virus Replication | 2018 |
Inflammatory, procoagulant markers and HIV residual viremia in patients receiving protease inhibitor monotherapy or triple drug therapy: a cross-sectional study.
Topics: Adult; Biomarkers; Cross-Sectional Studies; Cytokines; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Inflammation; Lopinavir; Male; Middle Aged; Ritonavir; Sulfonamides; Viremia | 2014 |
Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Cerebrospinal Fluid; Chromatography, High Pressure Liquid; Chromatography, Liquid; Darunavir; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Plasma; Ritonavir; Tandem Mass Spectrometry; Viral Load; Viremia; Young Adult | 2015 |
Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks.
Topics: Adult; Darunavir; DNA, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Ritonavir; RNA, Viral; Sulfonamides; Viral Load; Viremia | 2012 |
7 other study(ies) available for darunavir and Viremia
| Article | Year |
|---|---|
Variable endothelial cell function restoration after initiation of two antiretroviral regimens in HIV-infected individuals.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; Darunavir; Endothelial Cells; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Reverse Transcriptase Inhibitors; Rilpivirine; Viral Load; Viremia | 2017 |
Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir/ritonavir monotherapy.
Topics: Adult; Cohort Studies; Darunavir; DNA, Viral; Female; HIV; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Prospective Studies; Proviruses; Real-Time Polymerase Chain Reaction; Ritonavir; Sulfonamides; Viral Load; Viremia | 2014 |
Effects of treatment with suppressive combination antiretroviral drug therapy and the histone deacetylase inhibitor suberoylanilide hydroxamic acid; (SAHA) on SIV-infected Chinese rhesus macaques.
Topics: Animals; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Darunavir; DNA, Viral; Drug Therapy, Combination; Female; Histone Deacetylase Inhibitors; Hydroxamic Acids; Macaca mulatta; Naphthyridines; Ritonavir; RNA, Viral; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Sulfonamides; Viremia; Virus Replication; Vorinostat | 2014 |
[HIV encephalopathy due to drug resistance despite 2-year suppression of HIV viremia by cART].
Topics: AIDS Dementia Complex; Anti-Retroviral Agents; Central Nervous System; Cognition Disorders; Darunavir; Disease Progression; Drug Resistance, Viral; Drug Substitution; HIV; HIV Infections; Humans; Male; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Ritonavir; RNA, Viral; Sulfonamides; Time Factors; Viremia; Zidovudine | 2014 |
Differential effects of viremia and microbial translocation on immune activation in HIV-infected patients throughout ritonavir-boosted darunavir monotherapy.
Topics: Adult; Bacterial Translocation; Biomarkers; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lymphocyte Activation; Male; Middle Aged; Prospective Studies; Ritonavir; Sulfonamides; Viral Load; Viremia | 2015 |
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Kaplan-Meier Estimate; Lopinavir; Male; Middle Aged; Outcome Assessment, Health Care; Proportional Hazards Models; Ritonavir; RNA, Viral; Viral Load; Viremia; Young Adult | 2017 |
A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model.
Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Darunavir; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Flow Cytometry; Fluorescent Antibody Technique; Macaca mulatta; Maraviroc; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Simian Acquired Immunodeficiency Syndrome; Sulfonamides; T-Lymphocyte Subsets; Tenofovir; Triazoles; Viral Load; Viremia | 2012 |